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Transfer of naive antigen-specific CD4
 

 
 T cells into lymphopenic mice that express an 
endogenous antigen as a systemic, secreted protein results in severe autoimmunity 
resembling graft-versus-host disease. T cells that respond to this endogenous antigen 
develop into effector cells that cause the disease. Recovery from this disease is associated 
with the subsequent generation of FoxP3
 

 
CD25
 

 
 regulatory cells in the periphery. Both 
pathogenic effector cells and protective regulatory cells develop from the same antigen-
specific T cell population after activation, and their generation may occur in parallel or 
sequentially. Interleukin (IL)-2 plays a dual role in this systemic T cell reaction. In the 
absence of IL-2, the acute disease is mild because of reduced T cell effector function, but 
a chronic and progressive disease develops late and is associated with a failure to generate 
FoxP3
 

 
 regulatory T (T reg) cells in the periphery. Thus, a peripheral T cell reaction to 
a systemic antigen goes through a phase of effector cell–mediated pathology followed by 
T reg cell–mediated recovery, and both require the growth factor IL-2.
 
Two of the fundamental properties of the
adaptive immune system are unresponsiveness
to self-antigens (self-tolerance) and a steady state
in terms of total lymphocyte numbers (homeo-
stasis) (1–5). Disruption of self-tolerance and
homeostasis has the potential of triggering
pathologic immune reactions against a variety
of self-antigens. The mechanisms that prevent
such immune reactions are of great interest
because defining these mechanisms and learn-
ing how to control systemic reactions against
self-antigens may be useful for understanding
and treating many types of diseases, not only
autoimmune disorders. For instance, in graft-
versus-host disease (GvHD), transplanted T
cells react against host minor alloantigens that
have many of the characteristics of self-antigens
(such as constitutive and persistent expression
in the absence of inflammation) (6, 7). In this
scenario, disruption of homeostasis may be a
major contributor to the fatality of the disease.
Additionally, immunodeficiency or lymphope-
nia has been linked to autoimmunity in human
disease and mouse models (8–10).
The goal of our
 
 
 
experiments was to develop
a monoclonal, antigen-specific model for a
pathologic reaction to an endogenous systemic
antigen that is presented like a self-antigen, i.e.,
continuously and in the absence of inflammatory
stimuli. We hypothesized that, analogous to
GvHD, tolerance can be broken by lympho-
penia. We were especially interested in ask-
ing whether autoreactive T cells develop into
pathogenic effector cells without any overt
stimulation (other than encounter with endog-
enous antigen), whether they also have the
ability to limit their own reactions, and what
the mechanisms underlying this self-limitation
are. With the recent interest in regulatory T (T
reg) lymphocytes as a major control mechanism
for immune responses (11–13), it has become
important to determine if the conditions of
antigen recognition that are needed to induce
T reg cells are different from those that generate
other T cell subsets. Many studies of antigen-
specific T reg cells have focused on the develop-
ment of so-called “natural” regulatory cells in the
thymus, and only recently has the occurrence
of peripherally generated T reg cells resembling
the thymically derived subset been described
using antigen delivery via an osmotic pump
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(14). However, little is known about the generation or func-
tional significance of peripherally generated T reg cells (15).
In addition, we have explored the role of the cytokine
IL-2 in the generation of effector and regulatory cells be-
cause of the recent realization that this cytokine has multiple,
and often opposing, functions in immune regulation and be-
cause many immune therapies, especially for cancer and graft
rejection, are based on administering or blocking IL-2 (16–
19). IL-2 is known to be a potent inducer of T cell prolifer-
ation and differentiation into effector cells (20, 21). On the
other hand, it is also required for the development of T reg
lymphocytes in the thymus (22) and may promote apoptotic
death of activated T cells (23, 24), thus contributing to ter-
mination of T cell responses. In fact, the lymphoproliferative
and autoimmune phenotype of KO mice in which IL-2 pro-
duction or signaling is disrupted indicates that the obligatory
function of this cytokine may be in maintaining self-toler-
ance and homeostasis (25–28). To date, the regulatory func-
tion of IL-2 has been inferred largely from the phenotype of
these germline KO mice. In such experimental systems, it is
difficult to precisely define the role of IL-2 in the relative
development of effector and T reg cells or to examine im-
mune responses specific for known antigens.
To address these issues, we have exploited an experimen-
tal system in which naive CD4
 

 
 T cells with a single TCR
specificity are transferred into mice expressing the cognate
antigen as a systemic secreted protein (29). In this model, the
antigen-recognizing T cells become functionally anergic and
are eliminated, restoring homeostasis. We have modified this
system by transferring the T cells into antigen-expressing
mice on a lymphocyte-deficient (Rag
 

 
/
 

 
) background. Un-
der these conditions, the systemic antigen triggers massive ac-
tivation of the antigen-specific T cells, leading to fulminant
autoimmunity that resembles acute GvHD. However, this
acute phase is followed by a phase in which the mice recover,
suggesting that the autoreactive T cells not only trigger au-
toimmunity but also eventually control the reaction. Because
the entire reaction has been converted to the response of a
monoclonal T cell population to a single antigen, we can de-
fine the T cell–intrinsic mechanisms that contribute to the es-
tablishment of tolerance. Our results show that recovery from
the systemic reaction is associated with the de novo genera-
tion of CD25
 

 
 T reg cells. These T reg cells express high lev-
els of FoxP3 mRNA and protein, and they develop faster
from cells that have been preactivated in vitro. The T reg
cells also develop in thymectomized animals, formally dem-
onstrating that they are generated in the periphery. Absence
of IL-2 results in less severe disease early, which is associated
with reduced effector function of the T cells. In striking con-
trast, at late time points, in the absence of IL-2 no T reg cells
are generated in the periphery, and the antigen-specific effec-
tor T cells undergo persistent expansion, accumulate in tis-
sues, and cause severe injury. Thus, the same T cell popula-
tion gives rise to both effector and T reg cells on recognition
of the same antigen, and IL-2 is the critical cytokine for both
phases of the response. The development of these two popu-
lations may occur sequentially or in parallel. The therapeutic
implications of these results are discussed.
 
RESULTS
A model of systemic T cell–mediated autoimmunity
 
The initial goal of this study was to define the mechanisms
that limit or control autoimmunity and homeostasis in a set-
ting where the only lymphocyte population that is present is
reactive with an endogenous antigen that is expressed as a
systemic protein. We hypothesized that transfer of T cells
that are specific for this antigen into a lymphopenic host
might result in autoimmunity. This hypothesis was spurred
by the clinical correlation of immunodeficiency with au-
toimmunity (8, 9) and the finding that some autoimmune
reactions in experimental animals are associated with lym-
phopenia (10). It was also supported by the notion that my-
eloablative or lymphocyte-depleting conditioning regimens
used for bone marrow transplantation alter homeostasis and
promote T cell responses to ubiquitously expressed antigens,
resulting in GvHD (30).
Figure 1. Lymphopenia promotes a systemic autoimmune reaction. 
106 purified CD4 DO11 Rag/ T cells were transferred into sOVA Tg 
Rag/ or nontransgenic Rag/ mice on day 0. (A) Survival is plotted over 
time as the percentage of surviving mice from three experiments with 
four to seven mice per each group. (B) Body weight is plotted over time as 
the percentage of the starting weight before T cell transfer. Data are 
pooled from six to eight mice per group. In this analysis, only mice that 
survived were included. Values represent means  SD. (C) Paraffin sections 
of the ear skin of BALB/c control, Rag/, and sOVA Tg Rag/ mice 7 d 
after T cell transfer were stained with H&E.
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To test this idea, we crossed transgenic mice that express a
secreted form of OVA systemically (sOVA Tg) on to a Rag
 

 
/
 

 
background and adoptively transferred naive, monoclonal
ovalbumin (OVA)-specific DO11.10 (DO11) CD4
 

 
 T cells
(from DO11 Rag
 

 
/
 

 
 mice) into these recipients. Within 1–2
wk the transfer recipients show clinical signs of acute disease
(ruffled fur and hunching), lose weight, and begin to die (Fig.
1, A and B). Histopathologic examination of the skin shows
massive infiltration of lymphocytes in the sOVA Tg Rag
 

 
/
 

 
recipients of DO11 cells (Fig. 1 C). The cellular infiltrates are
associated with edema and congested vessels in the dermis
and focal epidermal necrosis, which is characteristic of an
acute graft-versus-host reaction (31).
One of the strengths of this experimental system is that a
monoclonal T cell population reacting to a single antigen is
responsible for the disease. It is therefore possible to examine
these T cells and determine how their responses correlate
with disease development. To do this, we assayed the recipi-
ents for the numbers and functions of the transferred DO11
T cells at different times after transfer. The controls we have
used in these experiments are transfers of DO11 cells into
Rag
 

 
/
 

 
 recipients that do not produce OVA. In lympho-
penic mice not expressing the cognate antigen, the trans-
ferred DO11 T cells undergo slow homeostatic proliferation
with a fourfold increase in cell numbers between days 7 and
35 after transfer (Fig. 2, A and B), as has been previously de-
scribed (32, 33). In the sOVA Tg Rag
 

 
/
 

 
 recipients, the
transferred DO11 cells undergo rapid proliferation and mas-
sive expansion, resulting in a 
 

 
100-fold increase in cell
numbers by day 7, and these numbers are maintained for up
to 35 d (Fig. 2, A and B). Moreover, the T cells make large
amounts of IL-2 and IFN-
 

 
 (Fig. 2, C and D). These reac-
tions are in marked contrast to the responses seen in normal
(lymphocyte-sufficient) sOVA Tg recipients, in which T cell
expansion is modest (at least 10-fold less), transient (peaking
at approximately day 4 and declining by days 7–10), and not
accompanied by effector cytokine production, all of which
are indicative of tolerance (29). Thus, the pathologic reactions
and uncontrolled T cell activation in the antigen-expressing
lymphopenic hosts suggest that tolerance has failed.
 
Role of T reg cells in recovery from disease
 
Despite this acute systemic disease after transfer of DO11
cells into sOVA Tg Rag
 

 
/
 

 
 recipients, there is little or no
additional lethality after 2–3 wk subsequent to transfer, and
the surviving mice begin to gain weight and recover (Fig. 1
B). Because the DO11 cells are still present in large numbers
even as the mice are recovering, we hypothesized that re-
covery may be because of the generation of T reg cells. Be-
cause CD25
 

 
CD4
 

 
FoxP3
 

 
 T cells are not detectable in
DO11 Rag
 

 
/
 

 
 animals (see Fig. 4 and Fig. S1, available at
http://www.jem.org/cgi/content/full/jem.20050855/DC1)
and therefore could not be present in the transferred T cells,
any T reg cells that develop must be generated from the
transferred naive DO11 cells. As illustrated in a representa-
Figure 2. Expansion of antigen-recognizing T cells in lymphocyte-
deficient recipients. 106 purified CD4 DO11 Rag/ cells labeled with 
CFSE were transferred into sOVA Tg Rag/ mice, nontransgenic Rag/ 
mice, or normal BALB/c recipients on day 0. (A) Peripheral lymph nodes 
were harvested 5 d after transfer, and the CFSE profile of gated KJ1-
26CD4 cells was determined by flow cytometric analysis. (B) Peripheral 
lymph nodes were harvested at the indicated time points after transfer, 
and the total number of DO11 cells was determined by counting and a 
flow cytometric analysis of KJ1-26CD4 cells. Data are pooled from 
three experiments (n  5, sOVA Tg Rag/; n  9, Rag/). The horizontal 
lines indicate means. (C) Peripheral lymph node cells were harvested on 
day 4 after transfer, restimulated with OVA peptide and APCs, and stained 
for intracellular cytokines. All plots are gated on KJ1-26CD4 cells. 
Numbers refer to the percentage of cytokine-positive cells. Representative 
plots are shown from one experiment out of four with two mice per 
group. (D) Data are expressed as the percentage of cytokine-positive gated 
KJ1-26CD4 cells pooled from two mice per group from one representative 
experiment. Values represent means  SD.
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tive series of FACS plots in Fig. 3 A and summarized in Fig.
3 B, within 4 d after transfer most of the DO11 cells express
moderate to high levels of CD25, presumably as a result of
activation by the antigen. CD25 expression gradually de-
clines over 2 wk. However, at day 30–35 (Fig. 3, A and
D), a distinct new population of CD25
 
high
 
 cells has clearly
emerged, with most of these expressing high levels of
CD62L (Fig. 3 D). This CD25
 
high
 
CD62L
 

 
 population can
be detected as early as day 14 and gradually increases as a
percentage of the T cells. The CD25
 
high
 
 T cells do not pro-
duce any IL-2, IFN-
 

 
, or IL-4, suggesting that they may be
T reg cells in which cytokine production has been sup-
pressed (Fig. 3 C).
To ask if the CD25
 
high
 
 cells have suppressive activity, we
purified DO11 cells 30 d after transfer, separated them into
CD25-negative, -low, and -high fractions by cell sorting, and
tested the suppressive ability of each fraction in co-culture as-
says with naive DO11 cells. As shown in Fig. 3 D, the
CD25
 
high
 
 cells isolated 30 d after transfer have potent suppres-
sive activity in vitro. In addition, DO11 cells recovered 4 wk
after transfer into sOVA Tg Rag
 

 
/
 

 
 recipients are unable to
cause disease when transferred into another set of sOVA Tg
Rag
 

 
/
 

 
 mice (Fig. S2, available at http://www.jem.org/cgi/
content/full/jem.20050855/DC1). This result further sup-
ports the idea that T reg cells have developed as a result of
prolonged exposure to the antigen. We have found that
both CD25
 
neg/low
 
 and CD25
 
high
 
 cells are nonpathogenic on
transfer into a second antigen-expressing recipient, presum-
ably because even the CD25
 
neg/low
 
 cells rapidly develop into
CD25
 
high
 
 cells on repeat encounter with the antigen (Fig. S2).
Expression of FoxP3 mRNA and protein has been
demonstrated to be a functionally relevant marker for
CD4
 

 
CD25
 

 
 T reg cells (34, 35). Indeed, FoxP3 mRNA
expression is high in CD25
 
high
 
 DO11 Rag
 

 
/
 

 
 cells isolated
 
Figure 3. Peripheral development of effector cells and T reg cells.
 
 
10
 
6
 
 CD4
 

 
-purified DO11 Rag
 

 
/
 

 
 cells were transferred into sOVA Tg Rag
 

 
/
 

 
 
mice on day 0. (A) Peripheral lymph nodes were harvested at the indicated 
time points after transfer and analyzed for expression of KJ1-26
 

 
CD4
 

 
CD25
 

 
 
cells by flow cytometry. Histograms show CD25 expression gated on KJ1-
26
 

 
CD4
 

 
 cells from one representative mouse out of three experiments. 
(B) The table summarizes data pooled from two mice per group, based on 
gates shown in A. (C) Lymph node cells were harvested 30 d after transfer, 
restimulated with OVA peptide and APCs, and stained for intracellular 
cytokines. CD25 staining was done before permeabilization. All plots are 
gated on KJ1-26
 

 
CD4
 

 
 cells. Representative plots are shown from one 
experiment out of four with two mice per group. (D) Peripheral lymph node 
cells were harvested on day 30 after transfer and sorted for KJ1-26
 

 
CD4
 

 
 
and negative (Neg.), intermediate (Low), or high (High) levels of CD25 
expression as indicated in the FACS plot. The cells were co-cultured (CC) 
with sorted naive KJ1-26
 

 
CD4
 

 
CD25
 

 
 cells from DO11 Rag
 

 
/
 

 
 mice, and 
[
 
3
 
H]thymidine incorporation was assayed on day 3. (E) Lymph node and 
spleen cells from sOVA Tg Rag
 

 
/
 

 
 mice at day 30 after transfer were sorted 
on KJ1-26
 

 
CD4
 

 
CD25 negative (
 

 
), low, and high (
 

 
) expression and 
analyzed for FoxP3 mRNA by real-time fluorogenic RT-PCR. Thymic-
generated KJ1-26
 

 
CD4
 

 
CD25
 

 
 cells from DO11 
 

 
 RIP-mOVA mice were 
included as a positive control; naive DO11 Rag
 

 
/
 

 
 and KJ1-26
 

 
CD4
 

 
 cells 
recovered from sOVA Tg Rag
 

 
/
 

 
 mice on day 5 were included as negative 
controls. Data are pooled from two experiments. Values in D and E represent 
means 
 

 
 SD.
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from sOVA Tg Rag/ recipients 30 d after transfer (Fig. 3
E). Furthermore, FoxP3 mRNA levels are similar to those in
thymically generated CD4CD25 cells from DO11 
RiP-mOVA mice (29, 36). Surprisingly, FoxP3 expression
can also be detected in CD25neg and CD25low cells 30 d after
transfer, although it is lower than in the CD25high regulatory
population. In contrast, DO11 cells that are isolated from
sOVA Tg Rag/ recipients early (i.e., on day 5 after trans-
fer) or naive DO11 Rag/ cells do not express detectable
FoxP3 mRNA. Thus, FoxP3 expression may increase pro-
gressively after chronic antigen recognition and is highest in
cells that have the functional characteristics of T reg cells.
It is theoretically possible that the adoptively transferred
T cells migrate to the thymus and this is where the T reg
cells are generated. To test this, we examined T reg cell gen-
eration in thymectomized antigen-expressing recipients. Be-
cause of the small thymus, it is not possible to reliably
thymectomize the sOVA Tg Rag/ mice. We therefore set
up another system in which intact sOVA Tg mice were
thymectomized, lethally irradiated, and transplanted with
Rag/ bone marrow, again providing lymphopenic anti-
gen-expressing mice as recipients for transferred DO11
Rag/ cells. These recipients undergo similar clinical dete-
rioration with massive weight loss and subsequent recovery
as do sOVA Tg Rag/ mice (unpublished data). If DO11
cells are transferred into these sOVA Tg bone marrow chi-
meras, a CD25high population develops as it does in sOVA
Tg Rag/ recipients. The CD25high cells show regulatory
function in vitro, thus demonstrating that the development
of regulatory cells occurs in the periphery independently of
thymic selection (Fig. S3, available at http://www.jem.org/
cgi/content/full/jem.20050855/DC1).
Kinetics of development of T reg cells from naive 
and activated T cells
To dissect the differentiation pathway of the T reg cells, we
first examined the time it took to generate these cells with-
out or with a cycle of prior activation. DO11 Rag/ cells
were primed for 4 d with antigen and APCs in vitro. At this
time, all the T cells had cycled and up-regulated activation
markers such as CD25 (unpublished data). We have previ-
ously shown that T cells primed in this way develop into ef-
fector and memory cells on transfer into BALB/c mice (37).
When these activated DO11 cells are transferred into sOVA
Tg Rag/ mice, a population of CD25highFoxP3 T reg
cells develops within 4 d and the numbers of these increase
progressively (Fig. 4). Transfer of naive cells does not gener-
ate CD25highFoxP3 T reg cells until after days 10–12 (Figs.
3 and 4). Co-culture assays also show that CD25high DO11
cells recovered 10–12 d after transfer of activated cells have
suppressive activity but not after transfer of naive DO11 cells
(unpublished data). Consistent with these accelerated kinet-
ics of T reg cell development from primed cells, sOVA Tg
Rag/ mice that have been transferred with in vitro–acti-
vated cells do clinically better than recipients transferred
with naive cells, and in five independent experiments with a
total of 12 mice per group, no mortality has been observed
after transfer of in vitro–activated cells (unpublished data).
Thus, T reg cells appear more rapidly if the T cells have
been activated before encounter with systemic antigen.
To further define a possible relationship between effector
T cells and T reg cells, we analyzed the DO11 cells for intra-
cellular IFN- production as a marker of effector cells at the
same time points as for FoxP3 expression. These experi-
ments showed that IFN- cells appear after 4 d subsequent
to transfer of naive or activated DO11 T cells, increase
through days 10–12, and decrease by day 30. (Fig. 4 C). The
finding that there is a progressive increase in T reg cells and
decrease in IFN-–producing cells may suggest that the two
populations arise independently (and even reciprocally).
Consistent with this possibility, we have not found any cells
that simultaneously express IFN- and FoxP3 protein at day
30 by two-color stains (unpublished data). However, it is
also possible that the development of the T reg cell pheno-
Figure 4. T reg cells develop more rapidly from activated than 
from naive DO11 cells. Purified CD4 DO11 Rag/ cells were stimulated 
on mitomycin C–treated splenocytes in the presence of 1 g/ml OVA peptide 
for 4 d. 106 in vitro–activated DO11 Rag/ or naive DO11 Rag/ cells 
were transferred into sOVA Tg Rag/ on day 0. (A) FoxP3 expression of 
naive and in vitro–activated DO11 Rag/ cells before transfer. (B) Spleno-
cytes were harvested 4, 10, and 30 d after transfer. FoxP3 expression of 
gated KJ1-26CD4 cells was measured by flow cytometric analysis. 
Splenocytes were restimulated with OVA peptide and APCs and stained 
for IFN- on days 4, 10, and 30 after transfer. All plots are gated on KJ1-
26CD4 cells. Representative plots are shown from three experiments 
with two mice per group.
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type actively extinguishes the production of effector cyto-
kines, thus creating the impression that these are nonover-
lapping populations.
Role of IL-2 in the systemic T cell reaction
Having established a system in which a single antigen gener-
ated effector and regulatory cells from one monoclonal anti-
gen-specific T cell population, we were interested in asking
what stimuli might be responsible for generating these two cell
types. We have focused on the role of IL-2 because of the
demonstrated ability of this cytokine to both stimulate and ter-
minate T cell responses and the importance of therapeutic ap-
proaches targeting IL-2 or its receptor. IL-2 has been impli-
cated in the thymic generation of T reg cells, but its role in
peripheral T reg cell generation is unknown (38). For these ex-
periments, we transferred either WT DO11 cells (from DO11
Rag/ mice) into WT sOVA Tg Rag/ recipients or IL-2–
deficient DO11 cells (from DO11 Rag/ IL-2/ mice) into
antigen-expressing recipients that also lacked IL-2 (sOVA Tg
Rag/ IL-2/). Thus, in these experiments, IL-2 could be
supplied either by the transferred T cells or by another non-
lymphocytic cell population in the host, such as DCs (39), or it
was completely absent. Importantly, by crossing the sOVA Tg
IL-2/ and the DO11 IL-2/ mice with Rag/ mice, nei-
ther donor nor recipient develops the autoimmune and lym-
phoproliferative disease that develops in conventional IL-2
KOs (25, 26). Furthermore, DO11 Rag/ WT and DO11
Rag/ IL-2/ cells have a similar naive phenotype (Fig. S1),
and similar cell numbers can be recovered from the thymus
and peripheral lymphoid organs (unpublished data).
Figure 5. Delayed pathology in the absence of IL-2. 106 purified 
CD4 DO11 Rag/ cells (DOWT) were transferred into sOVA Tg Rag/ 
recipients or DO11 Rag/ IL-2/ (DOIL-2/) cells were transferred into 
sOVA Tg Rag/ IL-2/ mice. (A) Survival is plotted over time as the per-
centage of surviving mice from five experiments with a total of 19–37 
mice/group. Body weight is plotted over time as the percentage of the 
starting weight before T cell transfer. Data are pooled from three individual 
experiments with 8–13 mice/group. *, P 	 0.05 by t test. (B and C) Paraffin 
sections of ear skin of sOVA Tg Rag/ and sOVA Tg Rag/ IL-2/ mice 
10 (B) and 30 (C) d after T cell transfer were stained with H&E. Frozen sections 
were stained with anti-CD4 or KJ1-26. One representative section from 
each group is shown. Clinical scores calculated as described in Materials 
and methods based on eight parameters (ear swelling, eye swelling, foot 
swelling, hunching, movement, ruffled fur, alopecia, and scaling) are 
shown from sOVA Tg Rag/ and sOVA Rag/IL-2/ mice at days 10 
and 30. Values in B and C represent means  SD.
JEM VOL. 202, November 21, 2005 1381
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Inspection of the transfer recipients showed that, in the
first 1–2 wk after cell transfer, the IL-2/ recipients of
IL2/ DO11 Rag/ cells appear healthy and there is less
weight loss than when IL-2–producing DO11 Rag/ cells
are transferred into WT sOVA Tg recipients (Fig. 5 A). In
addition, the clinical score and the epidermal damage in the
skin at day 10 are also less in the absence of IL-2 (Fig. 5 B).
Strikingly, WT mice that survive the acute reaction begin to
gain weight and recover by clinical score, and by day 30
there is less dermal inflammation in the skin by histopathol-
ogy (Fig. 5, A and C). In contrast, when IL-2 is absent, the
weight loss is progressive (Fig. 5 A), the mice do not recover
by clinical score, and by day 30 the skin is severely inflamed
and the mice have almost complete alopecia (Fig. 5 C).
Thus, the absence of IL-2 leads to a persistent and progres-
sive pathologic reaction resembling chronic GvHD (40).
To correlate the disease phenotype with the T cell re-
sponse, we examined the status of the DO11 T cells in the
lymphoid organs of the transfer recipients. By day 10 after
transfer the numbers of cells recovered from mice lacking IL-2
are about twofold more than from WT mice, and this dif-
ference is even greater at day 30 (Fig. 6 A). If the transferred
DO11 cells lack IL-2, fewer cells produce IFN- than do
WT cells (WT, 0.58  106 vs. KO, 0.37  106; Fig. 6 B).
However, on day 30, even though the percentage of IFN-–
producing DO11 cells is lower in the absence of IL-2, the to-
tal numbers in lymphoid tissues are about the same as in the
presence of IL-2 (WT, 0.23  106 vs. KO, 0.27  106; Fig. 6
B). We have not detected IL-4–producing DO11 cells in the
absence of IL-2, suggesting that the reduced pathology early
and the chronic disease late are not attributable to an imbal-
anced Th2 cell reaction. Thus, systemic antigen recognition
in the absence of IL-2 has two effects: early in the course, the
inflammatory phenotype is ameliorated, whereas late after
adoptive transfer it leads to persistent pathology and greatly
increased numbers of the antigen-recognizing T cells.
One possible explanation for the increased cell numbers in
mice transferred with IL-2/ DO11 Rag/ cells could be a
resistance of the T cells to activation-induced cell death (23,
24). To test this hypothesis, we assayed sOVA Tg Rag/
mice transferred with DO11 Rag/ cells and sOVA Tg
Rag/ IL-2/ recipients transferred with DO11 Rag/ IL-
2/ cells for the number of apoptotic cells 30 d after transfer.
As shown in Fig. 6 C, T cells in both the sOVA Tg Rag/
and sOVA Tg Rag/ IL-2/ recipients have a comparable
fraction of Annexin V binding cells, an early marker of apop-
tosis. Naive DO11 Rag/ and DO11 Rag/ IL-2/ cells
show a similar and very low number of apoptotic cells by this
assay. Thus, the increased cell number in the absence of IL-2
cannot be explained by a reduced frequency of apoptotic cells.
Role of IL-2 in the development of T reg cells
Because peripherally generated T reg cells are likely involved
in recovery from disease (Fig. 3), it follows that in the ab-
sence of IL-2 failure to generate these T cells may be respon-
sible for the delayed, chronic reaction. To address this, we
examined sOVA Tg Rag/ IL-2/ mice that had been
transferred with IL-2/ DO11 cells for the numbers of
CD25 T cells. As shown in Fig. 7 A, at day 30 after transfer
few cells expressing CD25 can be detected but no distinct
CD25high population can be found if the DO11 cells are from
IL-2/ mice. This experimental system also allows us to es-
tablish the source of the cytokine (transferred T cells or host)
required for the generation of T reg cells. CD25high cells de-
velop from WT DO11 cells regardless of whether or not the
host produces IL-2, but CD25high cells do not develop if the
T cells cannot produce IL-2 (Fig. 7 A). Thus, IL-2 produc-
tion from cells other than lymphocytes (e.g., DCs) is not suf-
ficient for peripheral generation of CD25 T reg cells.
Figure 6. T cell expansion is not controlled in the absence of IL-2. 
106 DO11 Rag/ cells (DOWT) were transferred into sOVA Tg Rag/ 
recipients, or DO11 Rag/ IL-2/ (DOIL-2/) cells were transferred into 
sOVA Tg Rag/ IL-2/ mice. (A) Peripheral lymph node cells harvested on 
days 10 and 30 were gated on KJ1-26CD4, and the total number of 
DO11 cells was determined by counting and flow cytometry and normalized 
to the number of DO11 cells recovered from sOVA Tg Rag/ recipients on 
day 10 in each experiment. Data are pooled from two experiments. (B) The 
cells were restimulated with OVA peptide and APCs and stained for intra-
cellular cytokines. Each bar represents the mean percentage of cytokine-
positive cells in three to six mice per group. Values in A and B represent 
means  SD. (C) Peripheral lymph node cells harvested on day 30 were 
stained with KJ1-26, anti-CD4, anti-CD25, and Annexin V and analyzed by 
flow cytometry. Plots are gated on KJ1-26CD4CD25neg/low or CD25high 
cells from one representative mouse per group. Naive DO11 Rag/ WT 
and DO11 Rag/ IL-2/ cells were included as controls.
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IL-2 has been implicated in the generation and/or the
function of thymic T reg cells (38, 41). We have shown that
there are no CD25high T cells generated if the T cells are IL-2
deficient (Fig. 7 A). However, it could be possible that
CD25negative T reg cells exist but are not functional. Because
FoxP3 mRNA expression is an accepted marker for T reg
cells, we sorted DO11 Rag/ or DO11 Rag/ IL-2/
cells 30 d after transfer into sOVA Tg Rag/ WT or sOVA
Tg Rag/ IL-2/ recipients, respectively, and assayed the
cells for FoxP3 mRNA. As shown in Fig. 7 B, FoxP3 mRNA
expression is detectable only in the WT and not in the IL-2–
deficient DO11 T cells, indicating that IL-2 is critical for the
generation of FoxP3-positive T reg cells in the periphery.
DISCUSSION
Lymphocytes that respond to an antigen have the potential
of developing into several functionally and phenotypically
different populations. CD4 T cells can differentiate into ef-
fector cells (including Th1 and Th2 cell subsets), memory
cells, and regulatory cells. A major question in immunology
is how these fates are determined, and, more specifically,
what is the influence of the nature of the antigenic stimulus
and the conditions of stimulation. This question has been
addressed in great detail for Th1/Th2 cell differentiation but
is largely unanswered for regulatory cells. We were especially
interested in asking whether an endogenous ubiquitously ex-
pressed antigen is capable of inducing both effector and T
reg cells and whether there are distinct requirements for
these cell populations. The importance of this question is
that the choice between self-tolerance and autoimmunity
may be determined, to a substantial extent, by the balance
between effectors and regulators, and learning how to ma-
nipulate this balance has obvious therapeutic relevance.
To address this question, we have developed an experi-
mental system in which CD4 T cells specific for the protein
OVA are exposed to OVA expressed as a secreted, systemic
antigen in a lymphopenic host. In these lymphopenic anti-
gen-expressing mice, the antigen-recognizing T cells do not
become tolerant. Instead, the T cells expand massively, rap-
idly differentiate into IFN-–producing effector cells, and
cause a severe immune reaction (Figs. 1 and 2). Some of the
effector cells that develop in the lymphopenic recipients in-
filtrate the skin, where they cause severe epidermal necrosis
and lesions resembling acute GvHD. In many respects, this
sequence of events is similar to what one sees in GvHD
when transferred T cells react against host alloantigens (6, 7).
This reaction contrasts sharply with the T cell response seen
in antigen-expressing intact (lymphocyte-sufficient) hosts in
which the T cells become tolerant by a combination of an-
ergy and deletion (29).
Despite the severe pathology induced by antigen recog-
nition in lymphopenic recipients, within 2–3 weeks the sur-
viving mice begin to recover. Recovery is associated with
the development of CD25 T cells with the phenotypic and
functional properties of T reg cells. These cells are CD25high,
express high levels of the FoxP3 transcription factor, and
suppress T cell responses in co-cultures (Fig. 3). The appear-
ance of these cells also correlates with an inability of the
DO11 T cells to cause disease on retransfer into a new anti-
gen-expressing recipient (Fig. S2). The role of T reg cells in
controlling a variety of immune reactions is well established
(11, 12, 42). It is generally accepted that the majority of
CD4CD25 T reg cells are generated by self-antigen rec-
ognition in the thymus (15). It is known that T cells with
suppressive function, called Th3 or Tr1 cells, can be induced
from mature CD4 T cells by special culture conditions in
vitro (43–47), and one report has demonstrated that chronic
exposure of mature CD4 T cells to their cognate antigen
delivered via an osmotic pump can induce CD4CD25 T
reg cells in the periphery with the same properties as thymi-
cally derived T reg cells (14). We have set up a system in
which T reg cells are induced by an endogenously produced
antigen that has the properties of a self-antigen. The T reg
Figure 7. IL-2 is crucial for peripheral generation of CD25 cells. 
106 purified CD4 DO11 Rag/ cells (DOWT) or DO11 Rag/ IL-2/ 
(DOIL-2/) cells were transferred either into sOVA Tg Rag/ recipients or 
into sOVA Tg Rag/ IL-2/ mice. (A) Peripheral lymph node cells were 
harvested on day 30. CD25 expression on gated KJ1-26CD4 cells was 
analyzed by flow cytometry. Numbers refer to the percentages of CD25high 
cells. (B) Lymph node cells of sOVA Tg Rag/ recipients transferred with 
DO11 Rag/ cells or sOVA Tg Rag/ IL-2/ mice transferred with DO11 
Rag/ IL-2/ cells were sorted for KJ1-26CD4 cells on day 30 after 
transfer and analyzed for FoxP3 mRNA by real-time fluorogenic RT-PCR. 
Thymic-generated KJ1-26CD4CD25 cells from DO11  RIP-mOVA 
mice were included as a positive control. Data are pooled from two 
experiments. Values represent means  SD.
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cells generated in our system develop even in thymecto-
mized mice (Fig. S3), formally demonstrating that they arise
in peripheral tissues. Also, even though most of our experi-
ments have been done with Rag/ recipients, we obtained
similar results in a model using irradiation and bone marrow
reconstitution (Fig. S3), further emphasizing the relevance to
bone marrow transplantation therapy and GvHD in humans,
which, by nature, is a highly controlled setting.
The question remains as to what role peripherally gener-
ated T reg cells play in tolerance maintenance in normal (lym-
phocyte-sufficient) hosts. It is possible that under normal
circumstances, thymic-derived T reg cells are sufficient to
maintain self-tolerance. We have found that transfer of DO11
cells into lymphosufficient sOVA Tg mice leads to profound
deletion with few anergic cells remaining (29). Under these
circumstances, the transferred T cells may simply not encoun-
ter antigen for long enough to develop into T reg cells. T reg
cells may only be generated in the periphery if other defects
occur, such as breakdown of lymphocyte homeostasis. Also, in
lymphopenic hosts the transferred T cells do not have to com-
pete with endogenous cells for the growth factors and other
stimuli that may be needed for T reg cell generation.
An important question emerges from these findings: do
the T reg cells arise from effector cells or are these parallel
differentiation pathways? Our experiments demonstrate that
T reg cells develop more rapidly from cells that have been
stimulated with antigen ex vivo than from naive T cells (Fig.
4), suggesting that T reg cells can develop from activated
cells. Furthermore, T reg cells develop faster from CD25neg/low
cells that have been exposed to the antigen for a month than
from naive T cells (Fig. S2). By costaining for intracellular
FoxP3 and IFN-, we have found no overlap between
FoxP3 and IFN- populations. These data allow two pos-
sible interpretations: (a) T reg and effector cells develop in
parallel and independently from activated cells that have not
yet undergone effector differentiation or (b) T reg cells de-
velop from effector cells, but IFN- production is extin-
guished when the cells acquire the T reg cell phenotype.
Future experiments are directed at distinguishing these possi-
bilities. Importantly, the development of pathogenic effec-
tors and protective regulatory cells occurs in the same ani-
mal, and, therefore, in the presence of the same innate
immune responses, costimulators, or other overt stimuli. It is
conceivable that different populations of APCs induce effec-
tors and regulatory cells from the naive T lymphocytes, and
it is also possible that the effector T cells themselves alter an-
tigen presentation by interacting with APCs, which subse-
quently leads to preferential generation of T reg cells. Identi-
fying the stimuli that determine the balance between effector
and T reg cells may provide clues to the control of a variety
of T cell–dependent immune responses.
IL-2 has multiple and often opposing functions in im-
mune regulation (48, 49). Although IL-2 is a powerful T cell
growth factor in vitro, the analysis of KO mice lacking IL-2
or IL-2 receptors has suggested that the major obligatory
function of IL-2 may be to control immune responses (25–
28). Studies with KO mice indicate that IL-2 is required for
thymic generation of T reg cells (22), but it may also play a
role in the function of T reg cells (41, 50). Thus, IL-2 is
clearly important for controlling immune responses; it is,
however, unclear from the KO mouse data whether IL-2
also plays an obligatory role in stimulating immune responses
or if its absence can be compensated for by other cytokines
in vivo. Our experiments formally prove the dual functions
of IL-2 in a model of antigen-specific systemic immune dis-
ease. The absence of IL-2 leads to a mild acute disease early,
with less pathology and no lethality (Fig. 5). In the absence
of IL-2, DO11 cells produce less IFN- (Fig. 6 B), and the
total number of IFN-–producing cells is also reduced.
These data suggest that the worse clinical disease in the WT
setting early is mediated by cytokines that may include IFN-.
It is conceivable that IL-2 in the WT recipients also pro-
motes the production of other proinflammatory Th1 cyto-
kines such as TNF-
, or IL-2 may activate other cell popula-
tions such as NK cells that may contribute to the phenotype.
In contrast to the early amelioration of disease, the ab-
sence of IL-2 leads to a failure to recover from the disease
and the development of a chronic reaction (Fig. 5). This fail-
ure to recover seems to be dependent on the massive infiltra-
tion of lymphocytes in the periphery, as shown by skin his-
tology and clinical score (Fig. 5 C), and is associated with a
failure to generate CD25 T cells (Fig. 7). Our results dem-
onstrate that IL-2 is required for T reg cell generation in the
periphery. The lack of FoxP3-expressing cells in the absence
of IL-2 indicates that T reg cells do not develop in the ab-
sence of IL-2, rather than being present but nonfunctional.
This is in contrast to a previous study that showed normal
FoxP3 expression in thymocytes of IL-2–deficient mice (51).
The absolute dependence on IL-2 in our system could
therefore be one of the differences between thymically and
peripherally generated T reg cells. Our experiments also
show that T cells, not nonlymphocyte populations such as
DCs, must produce the IL-2 in order to develop into T reg
cells (Fig. 7). When the development of T reg cells fails be-
cause of an inability to produce IL-2, the antigen-stimulated
T cells continue to expand (Fig. 6). However, we cannot
differentiate whether the IL-2 has to be produced by the T
cells developing into T reg cells in an autocrine fashion or
whether paracrine IL-2 that could be provided by CD25low
effector cells is sufficient for T reg cell development, as has
been suggested by others (51, 52).
The analysis of systemic immune reactions, as in autoim-
munity and GvHD, are important for the development of
clinical therapies for these immunologic diseases. Among
the many treatments that have been tried in such diseases,
one targeted therapy that has received some attention re-
cently is cytokine antagonism, particularly blocking the IL-
2/IL-2R pathway (18, 19, 53). Our results clearly raise cau-
tion about the usefulness and timing of IL-2 blockade for
controlling pathologic immune reactions. It may be that an
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acute blockade of IL-2 action will result in reduced T cell
expansion and reduced development of effector cells, which
may ameliorate pathologic immune reactions. This is con-
sistent with several clinical studies in which blockade of the
IL-2/IL-2R pathway leads to reduced incidence of acute
GvHD (54–56). However, prolonged inhibition of IL-2
may promote late, uncontrolled immune responses and pre-
disposition to persistent chronic GvHD. In fact, a recent re-
port has also suggested that IL-2R blockade in conjunction
with corticosteroids after bone marrow transplantation leads
to increased relapse- and nonrelapse-related mortality com-
pared with corticosteroids alone (57). Our data suggest that
IL-2R blockade at late time points after bone marrow trans-
plantation, in particular using myeloablative or T cell–
depleting regimens, may have detrimental effects, because
this strategy will also inhibit the subsequent development of
regulatory cells and may therefore reduce the potential of
endogenous control and restoration of homeostasis. The
idea that IL-2 antagonism may be beneficial early and harmful
late is applicable to other pathologic immune responses, as
in graft rejection and even autoimmune diseases. The tim-
ing of such treatment may, therefore, be the key to its suc-
cessful clinical application.
MATERIALS AND METHODS
Mice. All experimental mice were used at 6–12 wk of age. All mice
were age and sex matched 2 wk. BALB/c mice were purchased from
Charles River Laboratories. Transgenic mice expressing the DO11.10 TCR
(DO11), specific for the chicken OVA peptide (OVA323-339) in the context
of the MHC class II molecule I-Ad, were obtained from K. Murphy (Wash-
ington University, St. Louis, MO). All experiments were performed using
DO11 cells that had been crossed either onto a Rag1/ or Rag2/ back-
ground. For some experiments, DO11 Rag2/ mice were bred onto an
IL-2/ background. DO11  Rip-mOVA mice have been described pre-
viously (36). sOVA Tg on a BALB/c background, expressing a soluble form
of OVA in the serum under control of the Metallothionein promoter I, and
PCR typing for OVA expression have been described previously (unpub-
lished data) (29). sOVA Tg mice were bred onto a Rag2/ background or
onto a Rag2/ IL-2/ background. Animals that died or had to be killed
were excluded from all analyses except survival curves. Statistical analysis
comparing weight between groups was performed using two-tailed Stu-
dent’s t test, assuming equal variances.
Clinical scoring was done using the following parameters: ear swelling,
as measured by microcaliper in millimeters (0.25  0, 0.3  0.25,
0.35  0.5, 0.4  0.75, 0.45  1, 0.5  1.25, and 0.5  1.5
points, respectively); eye swelling (no, moderate, and severe  0, 0.5, and 1
points, respectively); foot swelling (no and yes  0 and 1 points, respec-
tively); ruffled fur (no and yes  0 and 1 points, respectively); hunching (no,
moderate, and severe  0, 0.5, and 1 points, respectively); movement (nor-
mal, moderately decreased, and severely decreased  0, 0.5, and 1 points, re-
spectively); alopecia (1 cm  1, 2 cm  2, and 2 cm  3 points, re-
spectively); and scaling (0.3 points per lesion on tail, paws, and ears).
In some experiments, the thymus of sOVA Tg mice was removed by
suction, and the mice were lethally irradiated (900 rad) and transplanted
with Rag/ bone marrow. Radioresistant CD4 cells were depleted with
GK1.5 antibody before adoptive transfer of DO11 Rag/ T cells.
All mice were bred and maintained in our pathogen-free facility in ac-
cordance with the guidelines of the Laboratory Animal Resource Center of
the University of California, San Francisco. All experiments were con-
ducted with the approval of the Committee on Animal Research of the
University of California, San Francisco.
Antibodies and flow cytometry. Lymph node cells and splenocytes
were stained with the clonotypic antibodies KJ1-26 (Caltag Laboratories),
anti-CD4 (GK1.5, H129.19, and RM4-5), anti-CD25 (PC61 and 7AD),
anti-CD62L (MEL-14), Annexin V, and FoxP3 (eBioscience). All antibod-
ies were obtained from BD Biosciences unless otherwise stated. Antibodies
were used as FITC, PE, PE–Cy7, PE–Texas red, allophycocyanin, or peri-
din chlorophyll protein conjugates. Fc-block (anti-CD16/CD32) was
added before staining. Flow cytometric analyses were done on a FACSCali-
bur with Cellquest Software (both from Becton Dickinson). Percentages
were rounded up after the first decimal place. Cells were sorted with a
cell sorter (MoFlo; DakoCytomation). For intracellular cytokine staining,
DO11 T cells recovered from peripheral lymph nodes or spleens of transfer
recipients were restimulated on mitomycin C–treated BALB/c splenocytes
for 14 h in the presence of 1 g/ml OVA peptide. 10 g/ml Brefeldin A
(Epicentre) was added for the final 2 h of stimulation. Cells were stained for
the intracellular cytokines IL-2, IFN-, and IL-4, with appropriate isotype
controls, and were analyzed by flow cytometry.
Cell preparations, purifications, and adoptive transfer. CD4 cells
for adoptive transfer were purified from spleens and lymph nodes using
Dynabeads according to the manufacturer’s protocol (Dynal). CD4 puri-
fied DO11 Rag/ or DO11 Rag/ IL-2/ cells were adoptively trans-
ferred into sOVA Tg Rag/ or sOVA Tg Rag/ IL-2/ recipients by
tail vein injection. For in vitro activation, CD4 cells were labeled with 5
M carboxyfluorescein diacetate succinimidyl ester (CFSE; Invitrogen) at
10  106 cells/ml for 10 min at 37C.
In vitro proliferation and suppressor assays. For co-culture assays,
5,000 sorted KJ1-26CD4CD25 T cells from DO11 Rag/ mice were
used as responders and stimulated on 25,000 APCs with 1 g/ml OVA in
200 l of RPMI 1640 with 10% FCS in 96-well plates (Costar). KJ1-
26CD4 cells from sOVA Tg Rag/ recipients that were harvested at the
time points indicated in the figures and sorted on the basis of high, interme-
diate, or no CD25 expression were used as suppressors. The ratio of re-
sponder/suppressor cells remained constant at 1:1. 1 Ci/well [3H]thymi-
dine was added during the final 16 h of culture, and incorporation was mea-
sured by scintillation counting at the time points indicated in the figures.
For in vitro activation, 0.25  106 CD4-purified and CFSE-labeled
DO11 Rag/ cells were stimulated on 2.5  106 mitomycin C–treated
splenocytes in the presence of 1 g/ml OVA peptide for 4 d. Cells were fi-
colled and rested overnight in 1 ng/ml IL-2 before injection.
Histology and immunohistochemistry. Tissues were fixed in 10%
neutral buffered formalin and embedded in paraffin. 5-m sections were cut
and stained with hematoxylin and eosin (H&E). For immunohistochemis-
try, tissues were immersed in OCT (TissueTek), flash frozen, cut into 5-m
sections, and stained with rat anti-CD4–Biotin (GK1.5; BD Biosciences) or
biotinylated KJ1-26 and subsequently stained with streptavidin–horseradish
peroxidase (BD Biosciences). Visualization was done with 3,3-diami-
nobenzidine (Sigma-Aldrich).
Real-time RT-PCR. Quantitative RT-PCR was performed using real-
time fluorogenic 5-nuclease PCR on a sequence detection system (ABI
Prism 7700; PE Biosystems) according to the manufacturer’s instructions
(TaqMan; Perkin Elmer). Total RNA was isolated using the Absolutely
RNA RT-PCR Miniprep Kit (Stratagene). To avoid contamination with
DNA, samples were treated with DNase (Ambion) before amplification and
reverse transcribed using Superscript II Kit for RT-PCR (Invitrogen).
Primer and probe sequences for FoxP3 and HPRT were used as published
(58, 59). FoxP3 transcript expression was normalized to HPRT abundance.
Online supplemental material. Fig. S1 demonstrates that DO11 Rag/
WT and DO11 Rag/ IL-2/ lymphocytes have a naive phenotype by
staining for CD25, CD69, and CD62L expression. Fig. S2 shows that
CD25neg/low DO11 T cells recovered 30 d after transfer into sOVA Tg
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Rag/ do not cause disease and rapidly develop a population of CD25high
cells on transfer into a new sOVA Tg Rag/ host. Fig. S3 demonstrates the
development of T reg cells in thymectomized sOVA Tg WT mice that
have been lethally irradiated and transplanted with Rag/ bone marrow
before transfer of DO11 Rag/ cells. Online supplemental material is
available at http://www.jem.org/cgi/content/full/jem.20050855/DC1).
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